Stem, Inc. (STEM) has disclosed a new risk, in the Corporate Activity and Growth category. Stem, Inc. faces significant risks in its attempts to ...

The stem cell market and the value of regenerative medicine stocks is expected to grow further ... including three in Phase 3 clinical studies targeting high-risk lymphomas and myeloma.

JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool recommends Stem. The Motley Fool has a disclosure policy.

Stem, Inc. engages in the provision of an energy ... performance metrics and investor preferences to help you find the right stocks for your investing style.

U.S. stocks plunged Tuesday as President Donald ... Erica Kollmann What's Going On With Stem Shares Tuesday? Stem shares are trading higher on Tuesday after the company announced it secured ...

Stem (NYSE:STEM – Get Free Report) had its target price boosted by equities research analysts at Roth Mkm from $0.35 to $0.40 in a note issued to investors on Wednesday,Benzinga reports. The firm ...

STEM – Get Free Report) have received an average rating of “Hold” from the eight research firms that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the ...